(Photo credits: Adobe Stock – )
(AOF) – According to its study results, the biotechnology company Adocia announces an exceptional weight loss of 5.5 kg with M1Pram in obese people with type 1 diabetes. M1Pram combines M1 insulin and pramlintide in a standard insulin pen. This loss was measured at 16 weeks of treatment in people with type 1 diabetes and a body mass index greater than 30 kg/m2. The satisfaction questionnaire clearly demonstrated better appetite control with M1Pram for 82.4% of patients (compared to 43.2% with Humalog).
Post-hoc analyzes revealed the greatest efficacy of M1Pram in a subpopulation of obese patients with a Body Mass Index (BMI) greater than 30 kg/m2.
Weight loss was 5.56 kilograms in the M1Pram group versus -0.57 kilograms in the Humalog group at 16 weeks of treatment, and weight loss had not plateaued by the end of the study.
“As more and more people with type 1 diabetes are overweight or obese, a product such as M1Pram allows these patients to lose weight, while maintaining glycemic control, which is an important outcome “, said Jay S. Skyler, Professor of Medicine at the Leonard M. Miller School of Medicine, University of Miami.
These results were presented at the 58th annual congress of the European Association for the Study of Diabetes (EASD) held in Stockholm from September 19 to 23, 2022.
Nine million people currently suffer from type 1 diabetes worldwide and this figure will double over the next few years. 65% of them are overweight and about 37% obese, in particular due to the anabolic effect of insulin used daily to regulate diabetes.
AOF – LEARN MORE
An inevitable race for new blockbusters
The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.